<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01781871</url>
  </required_header>
  <id_info>
    <org_study_id>HUCH</org_study_id>
    <nct_id>NCT01781871</nct_id>
  </id_info>
  <brief_title>Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Compared to the Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients</brief_title>
  <acronym>SOT13</acronym>
  <official_title>Immunogenicity of Repeated Dose 13-valent Pneumococcal Conjugate Vaccine Compared to the Existing Recommended Protocol of Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe Pneumococcal disease, such as bacteremia, meningitis and pneumonia, cause significant
      morbidity and mortality in both otherwise healthy adult population and in the
      immunocompromised patients. The incidence rate of invasive pneumococcal disease is
      considerably higher among organ transplant patients than in healthy individuals. Routine
      immunization with Pneumococcal vaccine is recommended pretransplant and once 3-5 years after
      the transplantation. The efficacy and immunogenicity of Pneumococcal polysaccharide
      vaccine(Pneumovax®) is suboptimal in this patient group. The conjugate Pneumococcal vaccine
      has been shown to be more immunogenic and safe in some other subgroups of immunocompromised
      patients. We intend to compare the immunogenicity of repeated dose 13-valent Pneumococcal
      conjugate vaccine (Prevenar13®)to the existing recommended protocol of Pneumococcal
      polysaccharide vaccine (Pneumovax®) in adult kidney and liver transplant patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">October 4, 2017</completion_date>
  <primary_completion_date type="Actual">October 4, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline serum serotype specific immunoglobulin G (IgG) antibodies to 13 polysaccharides and their opsonophagocytic activity (OPA) after the first vaccination</measure>
    <time_frame>baseline and 4 weeks after the first vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline serum serotype specific IgG antibodies to 13 polysaccharides and their opsonophagocytic activity (OPA) after the second Prevenar vaccination</measure>
    <time_frame>baseline and 4 weeks after the second vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>vaccination reactions</measure>
    <time_frame>from vaccination upto 1 week</time_frame>
    <description>Questionaire and phone interview assessment of vaccination reactions and adverse effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rejection</measure>
    <time_frame>at 1 and 2 months after the vaccination</time_frame>
    <description>Urine analyses and creatinine measurement with kidney transplant patients. Alanine aminotransferase measurement with liver transplant patients.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Prevenar13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>68 kidney transplant patients vaccinated with Prevenar13 as they enter the transplant waiting list. Pre- and postvaccination serotype specific ELISA and OPA measured. Revaccination at 6 months after the transplantation with Prevenar13, again pre- and postvaccination serotype specific ELISA and OPA measured</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pneumovax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>68 kidney transplant patients vaccinated with Pneumovax as they enter the transplant waiting list, serotype specific ELISA and OPA measured before and after the vaccination. At six and seven months after transplantation ELISA and OPA measured parallel to the experimental group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>liver Prevenar13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 liver transplant patients vaccinated with Prevenar13 once they enter the transplant waiting list. Serotype specific ELISA and OPA measured before and after the vaccination. Revaccinated with Prevenar13 at 6 months after the transplantation. ELISa and OPA measured pre- and postvaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>liver Pneumovax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 liver transplant patients vaccinated with Pneumovax once they enter the transplant waiting list. Serotype specific ELISA and OPA measured pre- and postvaccination. At 6 and 7 months posttransplant ELISA and OPA measured parallel to the experimental group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar13</intervention_name>
    <description>Prevenar13 0.5ml injected intramuscularly (im.) at day 1 and at 6 months after the transplantation.</description>
    <arm_group_label>Prevenar13</arm_group_label>
    <arm_group_label>liver Prevenar13</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumovax</intervention_name>
    <description>0.5ml Pneumovax injected intramuscularly at day 1.</description>
    <arm_group_label>Pneumovax</arm_group_label>
    <arm_group_label>liver Pneumovax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  consecutive new kidney or liver transplantation in our center

          -  kidney or liver retransplantation in our center

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Previous Pneumococcal vaccination &lt; 3 years ago

          -  Febrile illness at the time of vaccination

          -  Any sign of graft failure or rejection at the time of vaccination

          -  Splenectomy

          -  Pregnancy

          -  Critically ill patient due to any cause, including terminal uncompensated liver
             disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veli-Jukka Anttila, MD,PhD,Docent</last_name>
    <role>Principal Investigator</role>
    <affiliation>HUCH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <state>HUS</state>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heikki Saha</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2012</study_first_submitted>
  <study_first_submitted_qc>January 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2013</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Mari Eriksson</investigator_full_name>
    <investigator_title>MD, doctor of Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>Pneumococcal vaccination</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>solid organ transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

